阿帕替尼联合放疗治疗三阴乳腺癌脑转移的疗效观察  

Clinical obserwation of treatment in triple-negative breast cancer patients with brain metastases received radiotheray combined with Apatinib

作　　者：邹乐乐[1] 

机构地区：[1]河南省南阳市第二人民医院,473000

出　　处：《首都食品与医药》2020年第5期92-92,共1页Capital Food Medicine

摘　　要：目的本研究对三阴乳腺癌脑转移使用甲磺酸阿帕替尼的临床疗效和安全性进行分析。方法回顾性分析32例三阴乳腺癌脑转移患者的临床资料,所有患者均接受全脑放疗联合阿帕替尼治疗,直到疾病进展或发生不可耐受的毒副反应。结果全组32例患者的有效率和疾病控制率分别为90.6%和100%。结论阿帕替尼对三阴乳腺癌脑转移患者有效率较高且耐受性好。Objective To evaluate the clinical efficacy and safety of apatinib mesylate for brain metastasis from triple negative breast cancer.Methods The clinical data of 32 patients with brain metastasis from triple negative breast cancer were retrospectively analyzed.All patients received whole brain radiotherapy combined with Apatinib until the disease progressed or intolerable toxicity occurred.Results The effective rate and disease control rate of 32 patients were 90.6% and 100% respectively.Conclusion Appatinib is effective and well tolerated in patients with brain metastasis from triple negative breast cancer.

关 键 词：阿帕替尼 三阴乳腺癌 脑转移 全脑放疗 

分 类 号：R737.9[医药卫生—肿瘤]